Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta-Analysis of Placebo-Controlled Trials

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

6 randomized controlled trials (RCTs) with a total of 424 subjects and 751 patient-years of follow-up were included in this meta-analysis. The purpose of this study was to determine the effectiveness of bisphosphonates in the prevention of fractures in patients with osteogenesis imperfecta. Pooled results demonstrated that bisphosphonates did not significantly reduce the proportion of patients with fracture, but may reduce the risk of fractures in osteogenesis imperfecta patients. These result should be interpreted with caution as there were few studies identified comparing bisphosphonates to placebo in this patient population, and the majority of these studies were powered to detect differences in bone mineral density and not incidence of fracture. Further, appropriately powered studies are need on this topic to provide clarity.